Phase I trial, IQVIA Biotech code: Breye-C22-1005

Phase I trial, IQVIA Biotech code: Breye-C22-1005 [The full scientific title will be published within 30 months after the end of the trial]

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13284995

Enrollment

Registered

2023-11-06

Start date

2023-10-31

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. Eye Diseases

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Exclusion criteria

Exclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Design outcomes

Primary

Measure	Time frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.	—

Secondary

Measure	Time frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended	—

Countries

Germany, United Kingdom

Contacts

Public ContactPhillip Burgess

phillip.burgess@liverpoolft.nhs.uk+44 7 984 530 613

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026